Kailankangas, V
Katayama, S
Gröndahl-Yli-Hannuksela, K
Vilhonen, J
Tervaniemi, MH
Rantakokko-Jalava, K
Seiskari, T
Lönnqvist, E
Kere, J
Oksi, J
Syrjänen, J
Vuopio, J
Funding for this research was provided by:
Tampere University
Article History
Received: 5 February 2024
Accepted: 5 June 2024
First Online: 12 June 2024
Declarations
:
: The study protocol was approved by the Regional Ethics Committee of the Expert Responsibility Area of Tampere University Hospital and local research permissions were obtained from both research hospitals accordingly (permission numbers R18062, T05/026/18). The study was registered at ClinicalTrials.gov as ID NCT03507101. This study was conducted in accordance with the Declaration of Helsinki. Written consent was obtained from all study participants or from next of kin for sedated or intubated patients.
: JO has been a scientific advisor (advisory committee) to Astra-Zeneca, GlaxoSmithKline, MSD Finland, and Pfizer; received lecture honoraria from Advanz Pharma, Biocodex, GlaxoSmithKline, Pfizer, Professio, Roche, and Tillotts; and received coverage for congress travel/accommodation expenses from Gilead and Unimedic Pharma.